Compare Inovio Pharmaceuticals Inc (INO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SoundHound AI Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: SoundHound AI Inc is far larger — about 21.8× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and SoundHound AI Inc for 23 Days on average.
| INO | SOUN | |
|---|---|---|
Market Cap | $112.19M | $2.45B |
Volume | 3,201,278 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $2.60 | $21.40 |
52-Week Low | $0.66 | $5.39 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $83.51M | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
SoundHound AI (SOUN) trades at $5.52, down 1.95% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth ($169M in 2025 to $203M in 2026) but deepens net losses (-$14M to -$137M). Recent developments include expansion in banking and QSR sectors with new product OASYS Edge. Analyst consensus is strongly bullish with a $9.33 price target, though high valuation multiples and negative cash flow from operations pose concerns.
Outlook: Growth trajectory and market expansion offer upside potential, but profitability challenges and integration risks from acquisitions require careful monitoring. The stock presents a high-risk, high-reward opportunity in the competitive AI sector, with current price well below analyst targets suggesting potential appreciation if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
